UroGen secures exclusive option to license IntraGel's TumoCure for head and neck cancer; invests up to $7M

UroGen Pharma Ltd.

On Aug 18, 2026, UroGen U.S. entered an Option and Research License Agreement with IntraGel Therapeutics for TumoCure (head and neck cancer).
UroGen obtained exclusive option for worldwide license to develop/commercialize TumoCure using IntraGel's SRGel biodegradable hydrogel platform.
Also obtained options for additional SRGel-based products with UroGen-designated compounds, plus non-exclusive research license.
UroGen agreed to invest up to $7,000,000 in IntraGel equity via Securities Purchase Agreement on same date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.